Table 2 Biopathological characteristics
From: Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study
Total (pT1a and pT1b) | pT1a | pT1b | |
|---|---|---|---|
N. of patients | 402 | 82 | 320 |
Histology | |||
Ductal | 336 (83.6%) | 70 (85.4%) | 266 (83.1%) |
Lobular | 38 (9.5%) | 7(8.5%) | 31 (9.7%) |
Mixed | 5 (1.2%) | 0(0.0%) | 5 (1.6%) |
Other | 23 (5.7%) | 5 (6.1%) | 18 (5.6%) |
Vascular invasion | |||
Yes | 30 (7.5%) | 3 (3.7%) | 27 (8.4%) |
No | 267 (66.4%) | 51(62.2%) | 216(67.5%) |
Unknown | 105 (26.1%) | 28(34.1%) | 77 (24.1%) |
Grading | |||
G1 | 101 (25.1%) | 18 (22.0%) | 83 (25.9%) |
G2 | 221(55.0%) | 46 (56.1%) | 175 (54.7%) |
G3 | 72 (17.9%) | 15 (18.3%) | 57 (17.8%) |
Unknown | 8 (2.0%) | 3 (3.7%) | 5 (1.6%) |
Proliferation index (Ki-67/MB1) | |||
0–18% | 283 (70.5%) | 53 (64.6%) | 230 (71.8%) |
19–29% | 52 (12.9%) | 17 (20.7%) | 35 (10.9%) |
≥ 30% | 54 (13.4%) | 7 (8.5%) | 47 (14.7%) |
Unknown | 13 (3.2%) | 5 (6.1%) | 8 (2.5%) |
ER status | |||
ER positive (≥ 10%) | 351 (87.3%) | 65 (80.5%) | 285 (89.1%) |
ER negative (0–9%) | 51 (12.7%) | 16 (19.5%) | 35 (10.9%) |
PgR status | |||
PgR positive (≥ 10%) | 300 (74.6%) | 54 (65.9%) | 246 (76.9%) |
PgR negative (0–9%) | 102 (25.4%) | 28 (34.1%) | 74 (23.1%) |
Hormonal status* | |||
ER and/or PgR positive | 354 (88.1%) | 65 (81.7%) | 287 (89.7%) |
ER and PgR negative | 48 (11.9%) | 15 (18.3%) | 33 (10.3%) |
HER2 status** | |||
Positive | 49 (12.2%) | 19 (23.2%) | 30 (9.3%) |
Negative | 344(85.6%) | 62 (75.6%) | 282(88.2%) |
Unknown | 9 (2.2%) | 1 (1.2%) | 8 (2.5%) |
pN status | |||
pN0 | 319 (79.4%) | 67 (81.7%) | 252 (78.8%) |
pN1 (1–3) | 74(18.4%) | 12(14.6%) | 62 (19.4%) |
pN2 (4–9) | 6(1.5%) | 2 (2.4%) | 4 (1.3%) |
pN3 (≥ 10) | 3(0.7%) | 1 (1.2%) | 2 (0.6%) |